

The GOG Highlight Reel

November 2022

A GOG Foundation, Inc. Educational Program

Friday, November 11, 2022





Larry J. Copeland, MD
The Ohio State University,
James Cancer Center
President, The GOG Foundation, Inc

Director of Diversity and Health Equity for Clinical Trials



Dr. Bhavana Pothuri
NYU Langone Health, Perlmutter Cancer Center
GOG Partners Associate Clinical Trial Advisors

THANK YOU

GOG SITES

OUR MISSION



To conduct clinical and translational research that positively impacts patients through the prevention and treatment of gynecologic malignancies

OUR VISION



To be the premier collaborative network for transformative research in gynecologic malignancies



GOG
Highlight Reel

LEARNING OBJECTIVES

Upon completion of the activities in this series, learners will demonstrate:

THE OVERALL OBJECTIVE FOR THIS SESSION IS TO SHOWCASE CLINICAL TRIALS AND OTHER NEWSWORTHY EDUCATION FROM MAJOR MEDICAL MEETINGS THROUGHOUT THE YEAR

Greater competence related to

- Selecting therapies and treatments for women with cervical, endometrial, and ovarian cancers

Increased knowledge regarding

- The current agents and regimens used in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers
- The key trial data for newer therapies in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers
- The current investigational agents and regimens under evaluation for the treatment of advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers

GOG FACULTY DISCLOSURE INFORMATION

NAME	Individual's Role(s) in Activity	Nothing To Disclose	DISCLOSURE <company & role>
Speaker/Moderators			
Robert Coleman, MD	Planning/Speaker		Honorarium: Abbvie, Agenus, Alkermes, AstraZeneca, Clovis, Epsilogen, Genmab/Seattle Genetics, Gradalis, GSK, Immunogen, Janssen, Myriad, Novocure, Oncoquest, Oncologie, Roche/Genentech
Bradley J. Monk, MD	Planning/Speaker		Honoraria: Consulting/Speaker: Agenus, Akeso, AstraZeneca, Aravive, Clovis, Eisai, Elevar, Genmab/Seattle Genetics, GOG Foundation, Gradalis, Iovance, Karyopharm, Merck, McKesson, Mersana, Myriad, Novocure, Pfizer, Roche/Genentech, Sandoz Tesaro/GSK, VBL
Ramez Eskander, MD	Speaker		Advisory Board/Consulting Fee/Speaking: AstraZeneca; Merck; Clovis; GSK, Myriad
Kathleen Moore, MD	Speaker		Advisory board: AstraZeneca, Aravive, Blueprint, Alkermes, OnxXema, Eisai, GSK, Elevar, Genentech, Immunogen, Merck, VBL, Mersana, Myriad
Bhavana Pothuri, MD	Speaker		Research funding support/ Ad Board fees: AstraZeneca, Celsion, Immunogen, Merck, Mersana, Seattle Genetics, Sutro, Takada, Tesaro, Clovis Oncology Advisory Board: Eisai, Lily, GOG Foundation
Leslie Randall, MD	Speaker		Consulting fee: Agenus, Clovis, Myriad, Mersana, GSK/Tesaro Research Grant/ Contractor: Merck, Pfizer
Angeles Alvarez Secord, MD	Speaker		Advisory Board: Myriad Contracted clinical trial research: AbbVie, AstraZeneca, Boehringer, Clovis, Eisai, Immunotep. Ltd, Merck, National Cancer Trial Network, Oncoquest, PharmaMar, Roche/Genentech, Seagen inc., Tesaro/GSK, VBL Therapeutics
Brian Slomovitz, MD	Speaker		Consultant: Abbvie, AstraZeneca, Clovis, GSK, Genentech, Merck, Myriad
Michelle Small	Staff	X	
Jill Reese	Staff	X	

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** *(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations.**

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An "ineligible company" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

GOG CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).

Accreditation Statement

The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

AMA PRA Category 1 Credits™

The GOG Foundation, Inc. designates this live activity for a maximum of 3.0 **AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

COMMERCIAL SUPPORTERS

The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium:

AstraZeneca, Seagen, Karyopharm, Mersana, Laekna Therapeutics and Immunogen

MODERATORS



Bradley J. Monk, MD


Bradley Monk, MD, Director,
University of Arizona College of
Medicine, Creighton University
School of Medicine at St. Joseph's
Hospital and HonorHealth
Phoenix, Arizona, USA



Robert Coleman, MD

US Oncology Research, Houston, Texas,
USA

FACULTY



- **Larry Copeland, MD**, The Ohio State University, James Cancer Center, Columbus, Ohio, USA
- **Ramez Eskander, MD**, UC San Diego, San Diego, California, USA
- **Thomas J. Herzog, MD**, University of Cincinnati, Cincinnati, Ohio, USA
- **Kathleen Moore, MD**, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA
- **David O'Malley, MD**, The Ohio State University, James Cancer Center, Columbus, Ohio, USA
- **Bhavana Pothuri, MD**, NYU Langone, New York City, New York, USA
- **Leslie Randall, MD**, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
- **Angeles Alvarez Secord, MD**, Duke University, Durham, North Carolina, USA
- **Brian Slomovitz, MD**, Mount Sinai Medical Center, Miami Beach, Florida, USA

AGENDA

Session Time	Session Details & Faculty Information
11:00 am - 11:05 am ET	Welcome & Introduction <ul style="list-style-type: none"> Larry J. Copeland, MD, The Ohio State University, James Cancer Center, Columbus, Ohio, USA
11:05 am - 11:40 am ET	Emerging opportunities in newly diagnosed advanced ovarian cancer <ul style="list-style-type: none"> Angeles Alvarez Secord, MD, MHSc, Director of Gynecologic Oncology Clinical Trials, Duke Cancer Center Institute, Durham, North Carolina, USA
11:40 am - 12:15 pm ET	Emerging opportunities in platinum-sensitive recurrent ovarian cancer <ul style="list-style-type: none"> Bhavana Pothuri, MD, NYU Langone, New York City, NY, USA
12:15 pm - 12:50 pm ET	Emerging opportunities in platinum-resistant recurrent ovarian cancer <ul style="list-style-type: none"> Ramez Eskander, MD, UC San Diego, San Diego, California, USA
12:50 pm - 1:10 pm ET	Update on ASCO and NCCN Ovarian Cancer Guidelines <ul style="list-style-type: none"> Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, OK, USA
1:10 pm - 1:30 pm ET	Emerging opportunities in cervical cancers <ul style="list-style-type: none"> Leslie Randall, MD, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
1:30 pm - 1:55 pm ET	Emerging opportunities in endometrial cancer <ul style="list-style-type: none"> Brian Slomovitz, MD, Mount Sinai Medical Center, Miami Beach, Florida, USA
1:55 pm - 2:00 pm ET	Wrap up and announcement of next GOG Highlight Reel at WAGO 2023 (June 14-17, 2023, Monterey, CA) <ul style="list-style-type: none"> Bradley Monk, MD, Director, University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital and HonorHealth Phoenix, Arizona, USA Robert Coleman, MD, US Oncology Research, Houston, Texas, USA